Chemotherapy – The University of Texas M.D. Anderson Cancer Center

Survival:8.5 months
Toxicity Grade:4
Country:United States
City/State/Province:Houston, Texas
Hospital:The University of Texas M.D. Anderson Cancer Center


Patients: This Phase II study involved 24 patients with malignant pleural mesothelioma

Treatment: The treatment consisted of the administration of the drug Doxil.

Toxicity: Toxicities included cardiac, mild elevations of alkaline phosphatase, nausea, and hematological. One patient had a grade 4 neutropenia.

Results: No objective responses were observed and the overall median survival was 37 weeks (8.5 months).

Support: The study was supported in part by Sequus Pharmaceuticals, Inc. Sequus manufactures Doxil.

Correspondence: Dong M. Shin, MD

Get your free copy of
“Surviving Mesothelioma” Today!